A fat-derived molecule the body makes itself, which builds up around the brain as the need for sleep grows. The one human trial found better memory scores but no sleep gain over placebo; everything else is animal or laboratory work. It lowers body temperature and movement in animals, loses effect within days, and adds to alcohol and sedative medicines. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Sleep latency | Under 20 minutes | The primary claimed effect |
| Sleep efficiency | 85% or higher | Detects fragmented sleep despite faster onset |
| Morning core temperature | 36.4–37.0 °C | Animal data show a dose-dependent temperature drop |
| Seated and standing blood pressure | Under 120/80 mmHg seated, no drop over 20 mmHg on standing | Oleamide relaxes small arteries in rats |
| Resting heart rate | 50–65 bpm | Screens for a sedation-related nervous-system shift |
| ALT | Under 25 U/L (men), under 20 U/L (women) | Clearance enzyme is concentrated in liver and gut |
| hs-CRP | Under 0.5 mg/L | Cell data suggest a pro-inflammatory push |
| Fasting glucose | 75–85 mg/dL | Rodent data suggest a glucose-tolerance effect |
| HbA1c | 4.8–5.3% | Confirms any glucose change over months |
| eGFR | 90 mL/min/1.73 m² or higher | Screens for the impairment that contraindicates use |
| Endogenous oleamide level | No established target exists; track change from the individual's own baseline instead | The only direct exposure marker |
Cadence: Review at one week, four weeks and three months; blood work repeated at three months, then every six to twelve months